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Received 19 Apr 2018; first review completed 15 May 2018; accepted in final form 14 Jun 2018ABSTRACT—As outlined in the ‘‘International Guidelines for Management of Sepsis and Septic Shock: 2016,’’ initial fluid
resuscitation and administration of antibiotics are key steps in the early management of sepsis and septic shock. However,
such clear guidelines do not exist for preclinical sepsis models. To address these shortcomings, the Wiggers-Bernard
conference on preclinical sepsis models was held in Vienna in May 2017. The participants reviewed 260 of the most highly
cited papers between 2003 and 2012 that used sepsismodels. The review demonstrated that over 70%of experiments either
did not use or failed to report resuscitation and/or antibiotic treatment. This information served as the basis to create a series
of recommendations and considerations for preclinical sepsis models; this Part III report details the recommendations for
fluid resuscitation and antibiotic treatment that should be addressed in sepsis models. Similar to human sepsis, fluid
resuscitation is recommended in the experimental setting unless part of the study. Iso-osmolar crystalloid solutions are
preferred. The administration route and its timing should be adjusted to the specific requirements of the model with
preference given to dynamic rather than static hemodynamic monitoring. Predefined endpoints for fluid resuscitation and
avoidance of fluid overload should be considered. Preclinical sepsis studies display serious inconsistencies in the use of
antimicrobial protocols. To remedy this, antimicrobials are recommended for preclinical studies, with choice and dose
adjusted to the specific sepsis model and pathogen (s). Ideally, the administration of antimicrobials should closely mimic
clinical practice, taking into account the drug’s pharmacokinetic profile, alterations in absorption, distribution and clearance,
and host factors such as age, weight, and comorbidities. These recommendations and considerations are proposed as ‘‘best
practices’’ for animal models of sepsis that should be implemented.
KEYWORDS—Antimicrobial therapy, fluid resuscitation, Minimum Quality Threshold in Pre-Clinical Sepsis Studies
(MQTiPSS), sepsis model, sepsis, septic shockINTRODUCTION
Panta rhei (everything flows)—according to Heraklit (500
BC); even the ancient Greeks were aware of the importance of
this aphorism. Although this was used in relation to the continu-
ous fluctuation of nature, it also reflects the ongoing changes in
humans and the necessity to maintain flow by fluid homeostasis.
Sepsis is currently defined as a life-threatening organ dysfunction
caused by dysregulated host response to infection (1, 2). Conse-
quently, eradication of the infection-causing microorganisms byCopyright © 2018 by the Shock Society. Unauthorize
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33source control and antibiotic treatment is mandatory. Septic
patients can be rapidly identified as being more likely to have
a poor outcome by the new bedside score termed quickSOFA
(qSOFA) (2). Septic shock, as the most severe subset of septic
patients, reveals circulatory and cellular/metabolic dysfunction
associated with a higher risk of mortality (1). Septic shock
patients can be clinically identified by vasopressor requirement
to maintain a mean arterial pressure (MAP) of 65 mmHg (or
greater) and a serum lactate level greater than 2mmol/L (18mg/
dL) in the absence of hypovolemia (1). As outlined in the
‘‘International Guidelines for Management of Sepsis and Septic
Shock: 2016,’’ initial fluid resuscitation and administration of
antibiotics are the crucial steps in the earlymanagement of sepsis
and septic shock in humans. Tomaintain an adequate circulation,
resuscitation should begin promptly, using at least 30mL/kg of
crystalloid fluid i.v. within the first 3 h, with frequent reassess-
ment of hemodynamic status (3). The latest guidelines alsod reproduction of this article is prohibited.
TABLE 1. Fluid resuscitation use in sepsis models (2003–2012*)
Fluid resuscitation: general If fluid resuscitation used: frequency of application Specific circulatory and/or organ support therapy†
used: 111
not used/not stated: 263
1x: 58
2–6x: 14
7–9x: 4
>9x: 11
continuous i.v.: 8
as needed: 3
not stated: 14
used: 12
not used/not stated: 362
*Collated data are obtained from review of the 260 most-cited papers (featuring total of 374 animal experiments) identified with ISI Web of Knowledge
database (using the query: sepsis model).
†Not fluid resuscitation.
34 SHOCK VOL. 51, No. 1 HELLMAN ET AL.recommend initiation of empiric i.v. antimicrobial therapywithin
1 h of sepsis/septic shock diagnosis (3). Notwithstanding the
lack of confirmation of benefit from fixed resuscitation protocols
such as early goal-directed therapy (EGDT) (ProCESS 2014;
ARISE 2014; ProMISe 2015) (4–6), the use of appropriate
antibiotic treatment and fluid resuscitation is beyond dispute.
Nevertheless, the potential risks of resuscitation-induced fluid
overload (7, 8) and increasing antimicrobial resistance should not
be ignored.
To address the above topics, an international Wiggers-Ber-
nard conference on sepsis modeling was organized inMay 2017
in Vienna. The goals of the meeting were to identify the
limitations of preclinical models and to propose a set of
guidelines, defined as the Minimum Quality Threshold in
Pre-Clinical Sepsis Studies (MQTiPSS; reference to Executive
Summary to be copublished in Shock), to enhance the transla-
tional value of current and future sepsis models. Before the
conference, participants conducted a literature review of the
260 most highly cited scientific articles on sepsis models
published between 2003 and 2012 as the basis for conference
discussions within six predefined working groups. This scru-
tiny revealedmany inadequacies in the use of fluid resuscitation
and antimicrobial protocols. For example, over 70% of experi-
ments either did not use or failed to report fluid resuscitation
and/or antibiotic treatment (Tables 1 and 2). Such a discrepancy
between experimental and clinical management significantly
limits the scientific impact and translational relevance (9, 10).
This is amplified further by the lack of comparability among the
available sepsis animal models due to the heterogeneity of their
study design and management protocols (11).
Consequently, the Wiggers-Bernard initiative has led to the
creation of three joint publications (references to Part I and II
papers to be simultaneously published in Shock) to serve as an
MQTiPSS guideline for establishing the basic conditions for
modeling of sepsis to improve their translational relevance.
This current Part III paper makes specific recommendations forCopyright © 2018 by the Shock Society. Unauthor
TABLE 2. Fluid Resuscitation Endpoints Working Group
Fluid Resuscitation (WG-5) 14. Fluid resuscitation is essential unless
15. Administer fluid resuscitation based o
16. Consider the specific sepsis model
17. Resuscitation is recommended by th
g. Consider using predefined endpoints f
h. Avoid fluid overloadpreclinical models of sepsis concerning fluid resuscitation and
antimicrobial treatment. The goal of the conference was to
create quality thresholds for future studies so that findings from
models are more clinically applicable and the studies them-
selves are better comparable across laboratories and/or species.METHODS
The Wiggers-Bernard conferences on shock, sepsis, and organ failure is an
opinion-exchange platform for international scientists organized by the Ludwig
Boltzmann Institute of Experimental and Clinical Traumatology in the AUVA
Research Center (LBI Trauma), Vienna, Austria (http://trauma.lbg.ac.at/en).
The conference series was named after two outstanding scientists, one from the
‘‘New World’’ (Dr. Carl Wiggers) and one from the ‘‘Old World’’ (Dr. Claude
Bernard), who devoted their careers to critical care medicine and experimental
science. LBI Trauma is responsible for the topic selection, whereas the Austrian
Society of Advancement of Research in Shock and Tissue Engineering provides
sponsorship for each Wiggers-Bernard conference.
To address the deficits regarding management guidelines and standardiza-
tion in the field of preclinical sepsis research, in May 2017 LBI Trauma
organized the 9th iteration of the Wiggers-Bernard conferences addressing Pre-
clinical Modeling in Sepsis: Exchanging Opinions and Forming Recommen-
dations. The key goal of the conference was to create publishable material that
identifies essential elements that should be included in preclinical sepsis studies
as defined by the MQTiPSS descriptor (12). A total of 31 experts from 12
countries (including five members of the Sepsis-3 definitions task force (2))
were invited to participate in the initiative based on their experience in
experimental, translational, and clinical research.
The initiative consisted of three phases a 3-month preparatory phase where
participants performed a systematic review of the 260 top cited publications
from 2003 to 2012 and identified the key modeling topics to be discussed;
development of guideline points and subsequent discussion in Vienna over
2 days, during which the participants drafted a list of guidelines; and post-
conference refinement of the created works.
The preparatory phase review was conducted using the ISI Web of Knowl-
edge database (using the query: sepsis model). The 260 most cited papers (the
citation range 50–743; referenced over 29,000 times in aggregate), featuring a
total of 374 animal experiments, were identified. The time frame was subjec-
tively defined as 10 consecutive years beginning from 2003 as the year of
publication of the second iteration of the International Sepsis Definitions (13,
14). The results of that survey pertinent to the topics covered in this paper are
collated in Tables 1 and 2. As the first analysis showed that mice were used in
79% of the 2003 to 2012 papers, a secondary smaller search was performed
using PubMed and this included all 2013 to 2017 studies (total of 190;
irrespective of the number of citations) focusing on murine sepsis models onlyized reproduction of this article is prohibited.
(WG): recommendations (R) and considerations (C)
part of the study
n the specific requirements of the model
for the timing of the start and continuation for fluid resuscitation
e application of iso-osmolar crystalloid solutions
R
or fluid resuscitation as deemed necessary C
TABLE 3. Antimicrobial use in sepsis models (2003–2012*)
Antimicrobials: general information Antimicrobials: specific types and number of times used Antimicrobials: frequency of application
used in infection models (IM): 51
not used/not stated in IM: 198
not applicable
(LPS and non-live bacteria models): 125
carbapenem: 33
cephalosporin: 7
penicillin family: 7
metronidazole: 4
polymyxin: 3
aminoglycoside: 2
fluoroquinolone: 2
vancomycin: 1
clindamycin: 1
clarithromycin: 1
trimethoprim: 1
streptomycin: 1
1x: 19
2–6x: 9
7–9x: 7
>9x: 1
pre-operative: 4
*Collated data are obtained from review of the 260 most-cited papers (featuring total of 374 animal experiments) identified with ISI Web of Knowledge
database (using the query: sepsis model). LPS, lipopolysaccharide.
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endpoints within the 2003 to 2012 period. Both analyses were used during
the meeting. Overall, the preparatory phase aimed at identification of the most
important concepts in animal sepsis modeling to be addressed at the Vienna
Wiggers-Bernard conference. Participants were allocated into six specific
thematic Working Groups (WGs): Study Design, Humane Modeling, Infection
Type, rgan Failure/Dysfunction, Fluid Resuscitation, and Antimicrobial
Therapy Endpoints.
At the conference phase, each WG separately drafted a set of guideline
points that was subsequently subjected to general discussion and streamlined
either for further refinement in WGs or dismissal (day 1). After improvements,
the proposed points were voted upon by all participants to see if a clear
consensus could be gained (day 2). Overall, the Wiggers-Bernard conference
participants reached consensus on 29 points; 20 at ‘‘recommendation’’ strength
and 9 at ‘‘consideration’’ strength (the WG-5/6 points are listed in Tables 3 and
4). Following the format used by the Sepsis-3 task force (15), at least 2/3 (over
65%) of the votes were required for approval of a proposed point. All consensus
points were reached either unanimously or with no more than 2 abstentions per
point (i.e., Recommendation 8). The ‘‘recommendation’’ strength indicates
virtually unanimous agreement among the 31 participants, regarding both the
content and the need for rapid implementation. Issues that require additional
discussion (in the opinion of the participants) before final recommendations
could be made were classified as considerations.
In the postconference phase, the work was primarily focused on the
finalization of the arguments/narrative to be included in the final MQTiPSS
publications. This task was accomplished by teleconferences and electronic-
based discussion among WGs using a modified Delphi method. Finally, a
writing committee (formed at the conference) together with all participants
developed an Executive Summary for MQTiPSS (reference to Executive
Summary to be copublished in Shock) and three full-size publications (refer-
ences to Part I and II papers to be simultaneously published in Shock). Each (of
the three) publication focuses upon the deliberations of two related WGs; this
current Part III paper provides detailed discussion on recommendations made
for Fluid Resuscitation and Antimicrobial Therapy Endpoints.
CHAPTER 1: FLUID RESUSCITATION
Sepsis is associated with disturbances in fluid homeostasis.
In general, treatment guidelines recommend correction of
hemodynamic abnormalities by administration of fluids as
standard care (16–18). There is increasing evidence that suc-
cessful fluid therapy needs to be tailored to individual patients
and/or their defined subgroups. Sepsis models closelyCopyright © 2018 by the Shock Society. Unauthorize
TABLE 4. Antimicrobial Treatment Endpoints Working Grou
Antimicrobial Therapy (WG-6) 18. Antimicrobials recommended f
19. Antimicrobials should be chose
20. Administration of antimicrobial
i. Antimicrobials should be initiatmimicking the clinical setting need to implement fluid resus-
citation to avoid cardiovascular deterioration to septic shock.
Experimental studies provide evidence for the therapeutic
efficacy of fluid resuscitation in improving a number of physi-
ological variables and the septic shock state (19–21). However,
the majority of findings have been obtained in models featuring
a hypodynamic circulation. This makes direct data extrapola-
tion to humans (and vice versa) difficult, given that septic
patients typically develop hyperdynamic shock conditions (22).
In animals, the definition of clinically relevant resuscitation
volumes that mimic hyperdynamic sepsis is difficult, although
such hyperdynamic models have been reported (23, 24). This,
and the compartmentalization and complexity of the patho-
physiological responses seen during sepsis, calls for clinically
relevant animal models.
Although fluid administration protocols for sepsis are clini-
cally well established, our literature survey revealed that this
therapeutic principle frequently lacks reverse translation to
animal models. Indeed, 70% of the scrutinized experiments
(years 2003–2012) lacked any fluid resuscitation regimen
(Table 1). In those that reported fluid use in sepsis models,
the majority relied upon a single dose of fluids to address the
expected fluid imbalance (Table 1). Of note, in only 3% of the
experiments a circulatory support, such as catecholamines, or
specific organ support was used and adjusted to fluid resusci-
tation endpoints (Table 1). Our subsequent smaller review of
190 murine sepsis studies in the years 2013 to 2017 showed that
fluid resuscitation was missing in 73% of the experiments. Of
note, the lack of fluid administration can be justified in certain
types of sepsis studies, but their investigative premise should be
always clearly delineated.
These survey data clearly underline the need to define
various minimum quality recommendations (displayed in
Table 2 and addressed in detail below). Summarizing, adequated reproduction of this article is prohibited.
p (WG): recommendations (R) and considerations (C)
or pre-clinical studies assessing potential human therapeutic
n based on the model and likely/known pathogen
s should mimic clinical practice
R
ed after sepsis is established. C
36 SHOCK VOL. 51, No. 1 HELLMAN ET AL.fluid administration is crucial during sepsis. Due to the loss of
endothelial integrity within the capillary bed, the restoration of
intravascular volume and, in consequence, the enhancement of
tissue oxygenation represent the major aim of fluid therapy.
Specific recommendations for fluid resuscitation
The conference discussed several specific recommendations
for preclinical models of sepsis to advance the use of these
models. The following recommendations and considerations
from the Fluid Resuscitation Endpoints Working Group are
numbered consecutively from the preceding companion papers
and start with recommendation 14.
Recommendation 14: fluid resuscitation is essential
unless part of the study
As the importance of fluid administration has been clearly
demonstrated in the clinical setting, and volume resuscitation is
a central part of established current human therapies (3), the
incorporation of fluid resuscitation into animal sepsis studies
should approximate that given to human care, thereby increas-
ing the clinical relevance of such models. A large body of
evidence exists in support of this apparently obvious concept.
Fluid administration should thus be an essential part of the
experimental design to separate sepsis-related events from
pathological events resulting solely from a circulatory decline
due to protracted hypovolemia (25–27). Furthermore, cardio-
vascular parameters are important determinants of (micro)-
perfusion and organ function, and thus strongly influence the
applicability of the model. Fluid administration improves (at
least partly) hypovolemia and alterations of perfusion pressure
induced by anesthesia. Application of more complex and
invasive monitoring techniques enhances comparability to
the human setting (28–31). The hemodynamic profile of
human sepsis is characterized by an initial hyperdynamic phase
followed by a hypodynamic period. Thus, fluid resuscitation is
needed in sepsis models to replicate the hyperdynamic cardio-
vascular state seen in the early, resuscitated phase of human
sepsis (23, 32, 33). In addition, fluid resuscitation ensures a
more standardized experimental environment, enables repro-
ducible and comparable measurements, and is essential to
ensure scientific quality (27, 34). Concerning the 3Rs princi-
ples, fluid administration is an effective means of reducing
animal suffering and unnecessary mortality (35, 36).
Recommendation 15: administer fluid resuscitation based
on the specific requirements of the model
In septic patients, the optimal rate and volume of fluid
resuscitation still remain uncertain (37–39). In most animal
studies, fluid bolus treatment has generally improved sepsis
survival (23, 40). Experimental animals can receive variable
amounts of fluids through a variety of administration routes,
including intravenous, subcutaneous, and intraperitoneal. The
different kinetics in the systemic volume load by these routes
need appropriate consideration in animal sepsis experiments.
In small animal models with limited intravenous access, both
peritoneal and subcutaneous routes are frequently used for fluid
resuscitation. Subcutaneous fluid bolus treatment, typically
used in small animal models, simulates an intravenousCopyright © 2018 by the Shock Society. Unauthorcontinuous infusion rather than a bolus dose. For example,
in geriatric patients subcutaneous rehydration has proved as
effective as intravenous therapy (41). However, the subcutane-
ous route, despite its ease, has limitations, for example, the risk
of variable absorption rates dependent on microperfusion dis-
turbances occurring during sepsis (42). To avoid electrolytes
moving from the intravascular space to the extravascular
(subcutaneous) space, isotonic solutions are recommended
for subcutaneous application. Considering irritation at the
application locus, an unbuffered 0.9% saline with a pH of
5.0 is irritating and painful when administered subcutaneously.
Buffered systems such as lactated Ringer’s solution (pH: 6.5) or
Plasmalyte (pH: 6.5–8.0) are less irritating and thus recom-
mended for subcutaneous administration. However, to closely
simulate the clinical setting, fluid resuscitation should ideally
be given via the intravenous route. The miniaturization of
experimental equipment enables a feasible use of i.v. catheters
even in small rodents. If an i.v. line is absent, fluid is recom-
mended to be administered in intermittent repetitive doses,
preferentially via an intraperitoneal route, to correct or prevent
hypovolemia (35).
Recommendation 16: consider the specific sepsis model
for the timing of the start and continuation of fluid
resuscitation
To avoid both fluid deficit and fluid overload, appropriate
monitoring of therapeutic interventions is needed.
Post- versus pre-/co-/administration—The timing of fluid
resuscitation should consider the type of model and the objec-
tives of the study. The 2016 SSC guidelines recommended that
treatment and initial fluid resuscitation should begin immedi-
ately on diagnosis (3). However, this occurs after presentation
of a sick patient with sepsis and organ dysfunction, and not
from the time of onset of the infection. Models of sepsis exhibit
considerable time variability in the development of (patho)-
physiological responses, which may negatively affect the value
of the obtained results, especially when the interventions are
performed using fixed treatment regimens. Some experimental
interventions may be executed too early (e.g., before sepsis has
developed), which likely results in some protective effects. In
many models, the onset of fluid support is synchronized with
administration of the infectious insult, which is justifiable only
if the focus of study is on the transition state from presepsis
development to the early stages of sepsis and shock (43). In the
clinical setting, patients rarely present de novo during the very
early stages of sepsis, and the impact of fluid resuscitation in
relation to timing requires further research. In this context,
clinical studies do not illustrate the same uniformly positive
response to fluid resuscitation. Posttreatment fluid resuscitation
can be initiated at a later time point, for example, after infection
becomes clinically evident, thus more closely mimicking the
downstream pathological characteristics of severe clinical sep-
sis (44). The use of implantable biotelemetry technology may
help to identify in real-time the thresholds for acute physiologic
deterioration (e.g., after CLP in rodents), enabling initiation of
treatment at the precise point of physiologic deterioration (45).
The impact of high-, intermediate-, and low-volume resuscita-
tion regimens on cardiovascular performance, the developmentized reproduction of this article is prohibited.
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come at various time points during sepsis all need investigation
to fill the existing knowledge gap (25). Fluid therapy has a
dose–effect dependency; side effects should be treated in the
same way as other medications, with adjustments in timing,
type, and dosing of fluid (46). Overall, if the study design
allows, fluid administration and/or vasopressor/inotropic sup-
port should be administered in a posttreatment (rather than a
pre- or co-treatment) fashion, using predefined target end-
points, to avoid both fluid overload and ongoing hypovolemia.
Fluid dosing according to hemodynamic targets—The goal
of fluid resuscitation is to combat hypovolemia and restore
perfusion (47). The 2016 SSC guidelines recommend restoring
euvolemia with i.v. fluids, more urgently initially, and then
more cautiously as the patient stabilizes. Fluid challenge is
advised as long as hemodynamic factors continue to improve
(3). Unlike previous iterations, the new guidelines do not
provide specific initial hemodynamic target values, with the
exception of MAP. A few studies have addressed the impact of
resuscitation volume on sepsis outcomes, but have often
focused on the impact of aggressive or high-volume fluid
resuscitation (27).
Sepsis is characterized by vasoplegia with loss of arterial
tone, vasodilation with sequestration of blood in the unstressed
blood compartment, and changes in ventricular function with
reduced compliance and reduced preload responsiveness. Data
suggest that a physiologic, hemodynamically guided restricted
approach to fluid therapy would be prudent and could improve
sepsis outcomes (44). Future research should focus on the
design of hyperdynamic animal sepsis models (better recapitu-
lating human sepsis), and on studies evaluating minimal fluid
strategies in the resuscitation phase.
Hemodynamic monitoring—Hemodynamic monitoring
guides not only therapeutic interventions, but also the diagnosis
of shock, assessment of volume status, fluid responsiveness,
and the need for vasopressor and/or inotropic support. How-
ever, only few experimental settings offer broad hemodynamic
monitoring. For example, echocardiography in a murine sepsis
model demonstrated that a hyperdynamic state could be
achieved with adequate fluid resuscitation (23). In a fluid
resuscitated long-term (3 days) rodent model of sepsis, out-
come could be determined from early hemodynamic readouts.
Significant differences in stroke volume and heart rate mea-
sured 6 h postinsult predicted 3-day mortality with high accu-
racy (48). Other monitoring methods include (1) pressure-
volume catheter measurements for comprehensive cardiac
hemodynamics, (2) transit-time volume flow measurement in
blood vessels, (3) ultrasound-dilution for cardiac function and
blood volume measurements, (4) noninvasive Doppler flow
velocity measurements to assess cardiac output, filling, and
ejection velocities, and (5) ultrasonic pulsewave velocity which
can be determined in large and small animals. As a standard for
freely moving rodents, radiotelemetry or mobile tethered sys-
tems can be used for blood pressure, oxygenation, temperature,
and other physiological parameters. Microcirculatory monitor-
ing can be performed by sidestream dark field imaging, laser
Doppler, or laser speckle contrast-based techniques, and isCopyright © 2018 by the Shock Society. Unauthorizetypically performed under anesthesia in a variety of vascular
beds (49).
Dynamic versus static monitoring—SSC guidelines suggest
that, when available, dynamic variables should be used over
static variables to predict fluid responsiveness (3). Elevation of
central venous pressure correlates with an exponential rise of
pressures in the right atrium, and thus CVP-driven protocols are
at risk of causing cardiac failure (47). In a meta-analysis Marik
et al. could not show that a static CVP value predicts fluid
responsiveness (50). In addition, elevated CVP correlated to
acute renal failure in sepsis (49). MAP-driven strategies also
failed to show advantages over perfusion-driven protocols in
reducing morbidity and mortality (51–54).
The decision whether to administer fluid or not can be best
guided by using dynamic variables such as pulse pressure
variation, stroke volume variation, or the passive leg raising
test (19–21, 25, 26), all of which can be realistically applied at
present to anesthetized large animals only. Besides hemody-
namic parameters, lactate clearance can be considered for the
guidance of fluid therapy (55) as it correlates with the success
of fluid therapy. Functional hemodynamics have been
described to a very limited extent in animal models of sepsis;
validation of this approach has been mainly reported in large
animal models assessing the response to a fluid challenge. In
both normo- and hypovolemic conditions of LPS-induced rat
pneumonia, peripherally derived pulse pressure variation (PPV)
was not reflected by centrally measured stroke volume varia-
tion (SVV) in the setting of increased total arterial compliance
(56). In conclusion, it appears reasonable to transfer the recent
clinical findings in the field of intravenous volume therapy to
animal models, with preference given to dynamic rather than
static hemodynamic monitoring (57).
Recommendation 17: resuscitation is recommended by
the application of iso-osmolar crystalloid solutions
Administration of 0.9% (physiological) saline may result
in metabolic acidosis as a result of chloride overload (58,
59). The mechanism of this so-called ‘‘hyperchloremic aci-
dosis,’’ which occurs despite the alkalizing effect of hemo-
dilution-induced hypoalbuminemia (58), is the result of the
interplay between an extracellular strong ion difference and
the concentration of nonvolatile weak acids (58, 60). Fluid
resuscitation with saline aggravated organ injury and
increased mortality in rodent models of hemodilution (61)
and sepsis (59). This suggests that iso-osmolar balanced
crystalloid solutions rather than saline should be used for
resuscitation. Although its role in human sepsis/septic shock
is not yet definitely settled (62), albumin should be the only
colloid resuscitation fluid used, accompanied by adequate
monitoring of proteinemia and/or albuminemia. Finally,
given the fundamentally different metabolic response to
stress in rodents (63–65), attention should be paid to avoid
hypoglycemia. Depending on the underlying hypothesis to be
investigated, vasopressor and/or inotropic support should be
used to allow for ‘‘. . . experiments with more advanced
supportive care. . .’’ which ‘‘. . . would allow for better mim-
icry of . . .multi-organ failure. . .’’ (66).d reproduction of this article is prohibited.
38 SHOCK VOL. 51, No. 1 HELLMAN ET AL.Consideration g: consider using predefined endpoints for
fluid resuscitation
The 2016 Surviving Sepsis Campaign recommends clinical
examination, hemodynamic assessment, and the use of
dynamic variables in estimating fluid responsiveness during
the initial fluid resuscitation of septic patients (3). In the 2008
Surviving Sepsis Campaign guidelines different endpoints for
the initial resuscitation were mandated (67), such as a central
venous pressure (CVP) of 8 to 12 mmHg, MAP more than 65
mmHg, and central venous or mixed venous oxygen saturation
above 70% or 65%, respectively. Rivers et al. recommended the
above static variables for the monitoring of fluid administration
during sepsis (68); however, their findings were not subse-
quently confirmed by several multicenter clinical trials (4–6).
Of note, in the current SSC guidelines (3), individualized
endpoints for fluid resuscitation are suggested in accordance
with underlying comorbidities (e.g., such as arterial hyperten-
sion) to improve immediate outcomes. In addition, in clinical
practice guidelines for resuscitation from traumatic shock (69),
the proposed resuscitation endpoints are categorized into global
and regional. Adaptation of such complex reverse translation
approaches to small laboratory animal models of sepsis is
technically challenging; their daily use implementation does
not appear realistic in the near future. Conversely, in larger
animals (e.g., pig, sheep), dynamic responses rather than static
monitoring (such as pulse pressure variation) may help to
implement fluid resuscitation endpoints. In septic patients,
for example, cardiac output monitoring, pulse pressure and
stroke volume variation, and IVC diameter and stroke volume
assessment by echocardiography have been suggested as
dynamic predictors of responsiveness to fluids and to guide
fluid administration (70). These and other measurement tools
should be verified and used in large animal models of sepsis.
This would not only allow testing new approaches for clinical
translation, but also ensure a parallel development of targeted
fluid resuscitation strategy between septic patients and animals.
The three recent EGDT randomized trials have not confirmed
benefits of targeting specific physiologic parameters in a
general population. Thus, the key clinical problem for fluid
resuscitation remains in identifying proper endpoints that suit
an individual patient, and defining optimal thresholds for them.
In this context, large animal sepsis models appear to constitute
an ideal testing platform for determination of valid and reliable
predefined endpoints and development of microtechnical tools
for their monitoring. Properly designed animal models of septic
shock testing various sets of predefined endpoints could mean-
ingfully advance progress in this particular field.
Consideration h: avoid fluid overload.
Although the deleterious effects of fluid overload per se are
well established (8, 47), there are no readouts available to define
possible threshold values for fluid overload, in particular under
conditions of sepsis-induced barrier dysfunction and increased
vascular permeability. Clearly, fluid resuscitation may achieve a
hyperdynamic hemodynamic state (23, 27, 32, 33, 71, 72) and,
thereby,more closelymimics the clinical scenario of resuscitated
hyperdynamic sepsis or septic shock. Nevertheless, aggressive
fluid resuscitation, despite a more stable, hyperdynamicCopyright © 2018 by the Shock Society. Unauthorcirculation, aggravated organ dysfunction and ultimately
increased mortality (71). This was most likely due to interstitial
edema resulting from barrier disruption (73). Hence, investiga-
tors should predefine the maximum amount of fluids to be
administered, and, if hemodynamic target values are to be
achieved, to incorporate vasopressor/inotropic treatment into
the experimental design. Furthermore, the animal should be
closely observed for the development of edema.CHAPTER 2: ANTIMICROBIAL THERAPY
Antimicrobial therapy plays a central role in the clinical
management of sepsis (3). The Surviving Sepsis Campaign
(SSC) guidelines recommend that i.v. antimicrobials be admin-
istered as soon as possible, ideally within 1 h of diagnosis (3).
They further recommend that empiric broad-spectrum antimi-
crobials be administered to cover likely pathogens, and subse-
quently be narrowed to cover identified pathogens based on
their antimicrobial sensitivities (3). However, antimicrobials
are not consistently used in animal sepsis studies. Indeed, our
systematic review of the 260 most cited papers using sepsis
models published between 2003 and 2012 suggest that anti-
biotics are underutilized. The majority of studies using infec-
tion models (74%) either did not use antimicrobials or did not
describe their use. Carbapenems were used most frequently
(50%), followed by other ß-lactams (22%). Other agents
included metronidazole (6%), aminoglycosides (5%), poly-
myxin (5%), fluoroquinolones (3%), vancomycin (2%), clin-
damycin (2%), clarithromycin (2%), and trimethoprim (2%).
Our review of 190 murine sepsis studies in the subsequent
5 years (2013–2017) showed that antimicrobials were still only
used in a minority of infection models (14%), with ß-lactams
being used most frequently (90%).
Consistent with clinical practice, we recommend that anti-
microbials be considered for preclinical studies assessing
potential human therapeutics (Table 4). The inclusion of appro-
priate antimicrobials should allow for assessment of such
therapies under clinically relevant conditions. However, as
discussed below, it is important to recognize that some anti-
microbials can impact significantly on the host which should be
taken into account when designing a given study. Finally, there
may be experimental situations that make it unnecessary or
even inappropriate to use antimicrobials, or that preclude use of
a specific agent. Examples include studies testing the antimi-
crobial properties of an experimental agent, or mechanistic
studies designed to understand a pathway or the role of a
specific mediator.
Specific recommendations for antimicrobial therapy
The following recommendations from the Antimicrobial
Therapy Endpoints working group are numbered consecutively
from the preceding chapter and start with recommendation 18.
Recommendation 18: antimicrobials are recommended for
preclinical studies assessing a potential human
therapeutic
Adequate early source control and early administration of
appropriate antimicrobials are considered central to theized reproduction of this article is prohibited.
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rarely undertaken in preclinical sepsis studies, the majority of
which involve peritoneal contamination with bacteria and
abscess formation (e.g., CLP model). Although the benefit
of early, appropriate antimicrobials may not be so great as
generally supposed (74), it is nevertheless a standard of care in
clinical practice that antimicrobials should be administered
promptly (3). Administration of antimicrobials is therefore
recommended when studying putative therapeutics, as they
are routinely administered in humans with sepsis (3). The
routine administration of antimicrobials in sepsis models
may alter the efficacy of the therapeutic agent being evaluated,
perhaps offering synergism (75–80). Thus, the absence of an
antibiotic treatment arm may potentially skew the final con-
clusions. Studies in animal models do show improved survival
with antibiotic treatment (23, 81–83). However, the impact is
minimal or absent in aged animals (81), which are more
reflective of human septic populations that are heavily skewed
toward the elderly. It is also important to define an optimal
dosing regimen to provide adequate but not excessive dosing of
antimicrobials over the duration of the experiment, a topic that
is also pertinent to human ICU patients (83, 84). Shorter
duration therapy has been shown to be effective in the CLP
model (83). Antimicrobial dosing will likely be both species-
and insult severity-dependent. This should ideally take into
account the altered pharmacokinetics that occur during sepsis,
for example, related to altered metabolism and excretion,
volumes of distribution and protein binding and, potentially,
augmented renal clearance (85). Antibiotic pharmacodynamics
are generally poorly understood in sepsis (85, 86) and are not
well characterized in animal models.
Antimicrobial toxicity is increasingly recognized, even in
healthy subjects. Antimicrobials affect the microbiome, mod-
ulate inflammatory pathways and immune function, bind and
neutralize bacterial toxins such as LPS, affect cellular metabo-
lism and mitochondrial function, and can affect the CNS (82,
87–93). These effects may be potentially amplified during
sepsis. Antimicrobials have also been postulated to augment
sepsis pathophysiology by generating Jarisch-Herxheimer
reactions and cytokine release that are well described with
first dose administration, particularly of cidal antibiotics that
destroy the bacterial cell wall (94). The large-scale, rapid
release of cell constituents such as endotoxin and DNA can
significantly enhance the host PAMP (pathogen-associated
microbial pattern) inflammatory response. However, the func-
tional relevance of antibiotic-induced endotoxin release in
animal models is unclear (95). Although improving survival,
cidal antibiotics temporarily increased inflammation and wors-
ened acute kidney injury in an experimental sepsis model (82).
Further study is needed in these areas to better understand the
benefits and risks of antimicrobial therapy, and establishment
of correct dosing regimens.
Recommendation 19: antimicrobials should be chosen
based on the model and likely/known pathogen
In humans, the failure to provide appropriate antimicrobial
therapies expeditiously has been associated with increased
morbidity and mortality (96–98). Antimicrobials for animalCopyright © 2018 by the Shock Society. Unauthorizestudies should be chosen with careful attention to the particular
model being used for a given study and the causative pathogen
(s). The timing of the first dose of antimicrobials should also be
chosen carefully (see also R-18), taking into account that the
interval between the exposure (to pathogen) to the development
of clinical infection varies between infections (e.g., pneumonia,
peritonitis, primary bacteremia, fungal infection). Thus, in
some situations it may be appropriate to provide antimicrobials
early (e.g., a Neisseria-induced meningococcal model),
whereas delayed administration may be appropriate for other
models (e.g., polymicrobial CLP peritonitis).
Although it may not be feasible to fully recreate the antimi-
crobial choices given to humans, whenever possible it is
recommended that the same or equivalent agents be used.
The SCC guidelines recommend that antimicrobials be tailored
to the pathogen (s), which vary widely between patients (3). A
similar approach should be considered in animal sepsis models,
with individualization of the antimicrobial regimen based on
the likely specific pathogen(s). Several basic concepts of
antimicrobial treatment follow.
Models involving monomicrobial bacterial infection should
be treated with a single antibiotic that likely covers the patho-
gen. For instance, methicillin-sensitive Staphylococcus aureus
can be treated with an appropriate ß-lactam, but methicillin-
resistant S. aureus should be treated with vancomycin or
similar. Escherichia coli could be treated with a second or
third generation cephalosporin or an aminoglycoside. Polymi-
crobial infections, such as would be expected to arise from
bowel perforation (e.g., CLP and CASP models) or fecal slurry
injection, can be treated with either a broad-spectrum single
agent such as a carbapenem, or a combination of agents that
cover gram-positive and gram-negative aerobic and anaerobic
bacteria. Fungal infections should be treated with an appropri-
ate antifungal agent. Antimicrobial resistance for a given
pathogen should be factored into decisions about
antimicrobials.
The site of infection may also influence the choice of
antimicrobial agent. Some antimicrobials are not effective
for certain infections despite in vitro pathogen sensitivity.
For instance, aminoglycosides are inactivated by low pH,
and thus may not be effective for treating abscesses (99).
Similarly, antimicrobials that do not effectively cross the blood
brain barrier may be inappropriate for CNS infections. Finally,
whether an antibiotic is cidal versus static may also be an
important factor; cidal antibiotics are often chosen for life-
threatening human infections, and thus may be appropriate for
animal models.
Finally, minimum inhibitory concentrations (MICs) are used
by diagnostic laboratories to assess the resistance of microbes
to antimicrobial agents (susceptible, intermediate-susceptible
and resistant) (100). As compared with non-ICU settings,
infections in ICU patients are often caused by pathogens with
higher MICs. Often the MIC of a specific strain of bacteria is
known. However, if the pathogen’s MIC is not known, con-
sideration should be given to defining the MIC before initiating
a study. This certainly cannot be demanded within current
standard experimental settings but could be considered when
specific microbial research aims are tested.d reproduction of this article is prohibited.
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should mimic clinical practice
Whenever antimicrobials are included in a study, we recom-
mend that their administration mimics clinical practice as
closely as possible. The following factors should be considered
when deciding on how to administer antimicrobials for a
given study.
Route of administration—In the majority of small rodent
sepsis studies antimicrobials are administered subcutaneously
(typically with fluid resuscitation) and, in seldom cases, intra-
peritoneally (e.g., in peritonitis). Indeed, in our survey of
animal sepsis studies published between 2003 and 2012, intra-
venous antimicrobials were only used in five (large animal)
experiments. This differs from the standard of care for humans
with sepsis, which is to deliver antimicrobials intravenously
(3). For practical reasons, subcutaneous delivery of antimicro-
bials is often necessary for small rodent models given that an
indwelling venous catheter may be impractical, whereas
repeated intravenous injection increases the burden on animals.
However, it is recommended that antimicrobials be adminis-
tered intravenously in studies using larger animals (e.g., rabbits,
pigs, dogs, and nonhuman primates), in which more complex
instrumentation is common.
Pharmacokinetic profile—Antimicrobial pharmacokinetics
differ between species. For example, the elimination half-life of
cephalosporins was shorter in mice and rats versus rabbits,
dogs, and monkeys (101). Clearance of garenoxacin differed in
rats, dogs, and monkeys (102), whereas absorption of moxi-
floxacin was more rapid in rats, dogs, and humans than in
monkeys and minipigs (103).
Alterations in absorption, distribution, and clearance of
drugs—Numerous factors contribute to the altered pharmacol-
ogy of antimicrobial agents in septic critically ill patients (104–
108). These include an increased volume of distribution, altered
protein binding, fluctuations in plasma clearance, the presence of
edema which can limit the absorption of drugs, and drug-drug
interactions (109–111). These alterations can lead to lesser or
higher levels of drug exposure (108, 112). Optimal antimicrobial
dosing regimens for human sepsis have still not been established.
For instance, although broad-spectrum b-lactam antibiotics are
considered appropriate for the treatment of ICU-acquired pneu-
monia (113) optimal administration (e.g., intermittent dosing vs.
continuous infusion) remains uncertain (114, 115).
Host factors—Advanced age, sex, and comorbidities are
among themost important contributors tomortality in both septic
patients and animal models (81, 116–120). These factors impact
upon pharmacokinetics and pharmacodynamics of antimicro-
bials, but this is poorly characterized in animal models. Preclini-
cal sepsis studies using two-hit models and/or various
comorbidities potentially constitute an attractive, clinically trans-
latable testing platform for establishing the influence of such
factors upon the efficacy of antimicrobial treatment regimens.
Consideration i: antimicrobials should be initiated after
sepsis is established—For preclinical studies antimicrobial
therapy should be initiated once sepsis is established, as is
the case in humans, and should take into account evolving
clinical practices. Factors to consider when deciding upon the
timing of the first dose of antimicrobials include the severityCopyright © 2018 by the Shock Society. Unauthorand type of preclinical sepsis model (e.g., pneumonia, perito-
nitis, bacterial, fungal, etc.), and the animal species.
Time course of infection/sepsis in animals versus humans—
Currently, many animal studies provide antimicrobials immedi-
ately or within a few hours following the infectious insult—the
period in which clinical symptoms of sepsis are either absent or
mild. However, patients are seldom treated in this early window
given that antimicrobial treatment is typically triggered at the
emergence of clear clinical symptoms. This makes the early
administration of antimicrobials less replicative of the human
condition (3). Furthermore, late provision of antibiotics starting
12 h after severe infection has been reported to allow animals to
develop organ dysfunction (44). This suggests that delayed
dosing may reasonably replicate the human condition as well
asmodulating the severity of the sepsismodel itself.As discussed
in the Part I companion paper (chapter 1; reference to Part I paper
to be simultaneously published in Shock), there is uncertainty
about the time course of sepsis in animal models relative to
humans. For instance, interspecies differences in the interval
between exposure to a pathogen and the development of clinical
infection are poorly understood. Factors that differ between
species, such as metabolic rates (accelerated in healthy rodents
compared to bigger species) and differences in leukocyte dis-
tributions could profoundly affect responses to a bacterial insult.
Additionally, quorum sensing bacteria may behave differently
between species. Thus, it is conceivable that bacteria differen-
tially express virulence genes and/or have different proliferation
rates in different species. Finally, many animal studies use highly
lethal models (e.g., high doses of pathogen, 2-hit models) which
leads to an earlier onset andmore rapid progression of sepsis than
seen in patients. These issues make it difficult to recommend
definitive time points for initiating antibiotics. Treatment should
however be initiated soon after the animal manifests clinical
signs of sepsis (e.g., lethargy, decreased locomotion, changes in
body temperature).
Evolving clinical practices—The evidence base underlying
benefit from early antimicrobial administration has been criti-
cized (74). A systematic review and meta-analysis showed no
significant mortality benefit from administering antibiotics
within 3 h of emergency department triage or within 1 h of
shock recognition in severe sepsis and septic shock (121).
Despite differences in conclusions of various studies, the
current standard of care in patients is to provide the first dose
of antimicrobials as early as possible after diagnosing sepsis
(i.e., organ dysfunction). It is thus reasonable to use a similar
strategy for animal studies (122), particularly if the goal is to
mimic current clinical practice. In future sepsis modeling
scenarios, the administration of antimicrobials could be
matched to the emergence of specific symptoms (that typically
prompt evaluation/diagnosis in patients) rather than by the
defined number of hours after an insult. There may be other
experimental goals that factor into decisions regarding the
timing of antimicrobials.SUMMARY
This Part III manuscript details the recommendations and
considerations of two of the six working groups from the 2017ized reproduction of this article is prohibited.
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Analysis of the top-cited preclinical sepsis papers showed
substantial heterogeneity with regard to the use of fluid resus-
citation and antimicrobial treatment. A number of factors come
into play when deciding on antimicrobial and fluid adminis-
tration in animal sepsis studies. These include the goals of the
experiment, the specifics of the model (microorganism, site of
infection, comorbidities such as renal or liver dysfunction, age),
and the animal species being used. Whenever antimicrobial
agents or fluids are administered in a preclinical study, we
recommend their administration mimics clinical practice as
closely as possible. It is hoped that the proposed set of
recommendations and considerations will serve to bring a level
of standardization to preclinical models of sepsis and, ulti-
mately, improve translatability of preclinical findings. We
acknowledge that new challenges based on new information
from the clinical and bench studies will continue to arise. A
close collaborative work between basic scientists and clinicians
is critical for a thoughtful (re)interpretation of any existing and
newly posited principles.
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